From Uruguay’s full legalization to the debate between regional leaders in Canada questioning the recreational deadline, and a variety of market news INN provides a roundup of the week in cannabis
Prometic Life Sciences announced new data from its Phase 2/3 trial of Ryplazym in patients with congenital plasminogen deficiency.
Prometic Life Sciences closes equity offering for gross proceeds of $61.7 million.
A quick look of some of the major events in the cannabis industry this week.
Q BioMed Inc. (OTCQB:QBIO), a biotechnology acceleration company, announced today that Christopher Manuele will join the Strontium 89 Chloride commercialization team.
Mr. Manuele is a results-oriented, innovative executive with thirty-five years of comprehensive US and International expertise in nuclear medicine and medical isotope production. A long-time veteran of Amersham Health and
Invictus MD (TSXV:IMH) is pleased to announce its inclusion in the Horizon Medical Marijuana Life Sciences ETF (TSX:HMMJ) (“HMMJ ETF”), which is trading, and is the first ETF to offer direct exposure to North American-listed stocks that operate in the legal medical cannabis industry.
Horizon Medical Marijuana Life Sciences ETF is
Maricann announced has been added to the Horizons Marijuana Life Sciences Index ETF.
RepliCel Life Sciences signed a collaborative research project agreement with the University of British Columbia.
Aequus Pharmaceuticals announced a research collaboration with Canada’s national drug development and commercialization center.
The Hydroponics Company announced a partnership with Phoenix Life Sciences to research, develop, manufacture, distribute and sell medical cannabis in Australia.